Pharmaceutical formulations containing flavouring substances with improved pharmaceutical properties

1. A solid pharmaceutical formulation comprising:

a. 15% by weight pradofloxacin;

b. 35% by weight microcrystalline cellulose;

c. 24% by weight lactose;

d. 5% by weight polyvinylpyrrolidone;

e. 10% by weight flavoring which is a mixture of proteins, fats, and carbohydrates, exclusing starch;

f. 7.5% by weight croscarmellose sodium;

g. 2.5% by weight colloidal silicon dioxide; and,

h. 1.0% by weight magnesium stearate and wherein the formulation excludes starch.

2. A process for producing a solid pharmaceutical formulation according to claim 1 , in which the flavoring is granulated with the colloidal silicon dioxide and with the pradofloxacin, the microcrystalline cellulose, lactose, polyvinylpyrrolidone, croscarmellose sodium, and magnesium stearate.